Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
The panel shares closing advice for patients with multiple myeloma receiving teclistamab, and community providers and nurse practitioners administering teclistamab to patients.
Samuel Edwards, MD, discusses the science behind physician burnout and how it can be prevented.
Examine the efficacy and safety of the BCMA-targeting bispecific antibody elranatamab as monotherapy and in combinations from the Phase 2 MagnetisMM-3 trial in patients with relapsed or refractory multiple myeloma.
Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Danazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.
Ritu Salani, MD, highlights data from the RUBY trial supporting the FDA approval of dostarlimab/chemotherapy for primary advanced endometrial cancer.
The recent Hot Topics section focuses on survival rates for patients with cholangiocarcinoma.
Before closing out their discussion on novel treatment approaches to metastatic CSPC, expert panelists share hope for further evolution in care.
The panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.
Investigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.
ABSTRACT Adolescents and young adults (AYAs) with cancer constitute approximately 70,000 patients diagnosed each year. Survival rates for AYAs with cancer have increased steadily in recent decades due to improvements in therapeutic regimens and early detection. Given the large and growing number of AYA cancer survivors, additional research is needed on the immediate and long-term psychosocial support required for this population including family planning and fertility. Fertility and fertility preservation in female AYAs, in particular, is historically understudied and has psychologically relevant ramifications distinct from male AYAs. Decision science can contribute to this area of oncological care and has implications for clinical encounters and research concerning female AYA patients with cancer. Patient-centered care and shared decision-making that integrates recent research regarding fertility preservation in the context of cancer treatment can improve outcomes for AYA cancer survivors.
Panelists discuss how unmet needs and future directions for GPRC5D bispecific therapy include improving accessibility, managing long-term safety, and exploring combination strategies to enhance treatment efficacy.
Ted A. James, MD, MHCM, FACS, spoke about integrating artificial intelligence into oncology care.
Panelists discuss key takeaways from the analysis and offer clinical pearls on incorporating prophylactic dexamethasone 8 mg into treatment with amivantamab and lazertinib for community colleagues.
The phase 2 LuminICE study shows potential for the AFM13/AB-101 combination in treating patients with relapsed or refractory CD30-positive lymphoma.
Axel Merseburger, MD, PhD, spoke about implementing the treatment combination of enzalutamide plus docetaxel/prednisone for progressive castration-resistant prostate cancer from the PRESIDE trial into the real-world.